Literature DB >> 7600191

Interleukin-1 and interleukin-1 antagonism in sepsis, systemic inflammatory response syndrome, and septic shock.

J H Pruitt, E M Copeland, L L Moldawer.   

Abstract

Interleukin-1 (IL-1) is one of several proinflammatory cytokines produced during infection, sepsis, and the systemic inflammatory response syndrome (SIRS) that serves to initiate the host inflammatory response and to integrate nonspecific immunity. Many of IL-1's biologic effects are beneficial to the host in times of stress, but when produced for extended periods of time or in excessive quantities, IL-1 contributes to morbidity and mortality. In fact, excessive IL-1 production has been directly linked to the development of hypotension, shock, multi-organ system failure, hematologic dyscrasia, and death in patients and animals with sepsis, SIRS, and septic shock. Recent research interest has focused on IL-1 inhibition to improve outcome in sepsis and septic shock. This article will review the role for IL-1 in sepsis and septic shock, and the function and status of the IL-1 receptors and IL-1 receptor antagonist in modulating IL-1 actions. The results of investigations of IL-1 inhibition in animal models and in human subjects with sepsis and septic shock will also be reviewed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7600191     DOI: 10.1097/00024382-199504000-00001

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  34 in total

Review 1.  [Intensive insulin therapy in sepsis. Improvement of survival chances?].

Authors:  M G Jeschke
Journal:  Anaesthesist       Date:  2003-12       Impact factor: 1.041

2.  Peritoneal lavage reduces lipopolysaccharide-induced elevation of serum TNF-alpha and IL-6 mortality in mice.

Authors:  K Zhao; I Kirman; I Tschepen; R Schwab; M E Weksler
Journal:  Inflammation       Date:  1997-08       Impact factor: 4.092

3.  Insulin-like growth factor I in combination with insulin-like growth factor binding protein 3 affects the hepatic acute phase response and hepatic morphology in thermally injured rats.

Authors:  M G Jeschke; D N Herndon; R E Barrow
Journal:  Ann Surg       Date:  2000-03       Impact factor: 12.969

Review 4.  Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases.

Authors:  D S Hallegua; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

5.  Insulinlike growth factor I plus insulinlike growth factor binding protein 3 attenuates the proinflammatory acute phase response in severely burned children.

Authors:  M G Jeschke; R E Barrow; D N Herndon
Journal:  Ann Surg       Date:  2000-02       Impact factor: 12.969

6.  Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice.

Authors:  E Hirsch; V M Irikura; S M Paul; D Hirsh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

7.  Insulin treatment improves hepatic morphology and function through modulation of hepatic signals after severe trauma.

Authors:  Dagmar Klein; Thomas Schubert; Raymund E Horch; Karl-Walter Jauch; Marc G Jeschke
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

8.  Insulin treatment improves the systemic inflammatory reaction to severe trauma.

Authors:  Marc G Jeschke; Dagmar Klein; David N Herndon
Journal:  Ann Surg       Date:  2004-04       Impact factor: 12.969

Review 9.  IL-1 receptor 2 (IL-1R2) and its role in immune regulation.

Authors:  Vanessa A Peters; Jennifer J Joesting; Gregory G Freund
Journal:  Brain Behav Immun       Date:  2012-11-27       Impact factor: 7.217

10.  Rapid Hemodynamic Deterioration and Death due to Acute Severe Refractory Septic Shock.

Authors:  Abhijeet Dhoble; Won Chung
Journal:  J Clin Med Res       Date:  2009-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.